External Source

Dr. Luke On The Future Of Combination Therapy In Melanoma

2016 1:01
Synopsis
Jason Luke, MD, assistant professor of Medicine, the University of Chicago Medicine, discusses what the future holds for ...

You Might Also Like

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma 1:06
Dr. Luke On The Future Role Of Immunotherapy Combinations In...
2017
Dr. Luke on Future Research With T-Cell Therapy in Melanoma 1:12
Dr. Luke On Future Research With T-cell Therapy In Melanoma
2020
Dr. Luke Discusses Combination Approaches on Horizon in Melanoma 1:41
Dr. Luke Discusses Combination Approaches On Horizon In Mela...
2015
Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma 0:52
Dr. Luke Discusses The Combination Of Epacadostat And Pembro...
2017
Dr. Luke Discusses the Controversy Surrounding Ipilimumab/Nivolumab Combo in Melanoma 1:57
Dr. Luke Discusses The Controversy Surrounding Ipilimumab/ni...
2017
Dr. Jason Luke Talks About Advances in how Melanoma is Diagnosed 1:09
Dr. Jason Luke Talks About Advances In How Melanoma Is Diagn...
2015
Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma 1:04
Dr. Luke On The Combination Of Pembrolizumab And T-vec For M...
2017
Dr. Luke on Treatment Options in Metastatic Melanoma 0:59
Dr. Luke On Treatment Options In Metastatic Melanoma
2019
Checkpoint Inhibitors: Combination Therapy in Melanoma 7:51
Checkpoint Inhibitors: Combination Therapy In Melanoma
2016
The Future of Novel Immunotherapy Combinations in Melanoma 1:29
The Future Of Novel Immunotherapy Combinations In Melanoma
2019
Dr. Luke Discusses the Combination of PD-1 and IDO Inhibitors in Melanoma 0:56
Dr. Luke Discusses The Combination Of Pd-1 And Ido Inhibitor...
2017
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.